PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33964466-9 2021 The LAT1/SLC7A5-specific inhibitor JPH203 was used to evaluate LAT1-transporter-mediated leucine transport. Leucine 89-96 solute carrier family 7 member 5 Homo sapiens 63-67 33964466-14 2021 Moreover, leucine transfer was inhibited by 10microM JPH203 confirming that Leu transport across the trophoblast monolayer is LAT1-dependent. Leucine 10-17 solute carrier family 7 member 5 Homo sapiens 126-130 33964466-14 2021 Moreover, leucine transfer was inhibited by 10microM JPH203 confirming that Leu transport across the trophoblast monolayer is LAT1-dependent. Leucine 76-79 solute carrier family 7 member 5 Homo sapiens 126-130 33521042-8 2020 LAT1 protein increased following training (p < 0.001) and increased more in PLA than LEU and WPC (p < 0.050). Leucine 85-88 solute carrier family 7 member 5 Homo sapiens 0-4 33953707-7 2021 In particular, the amino acid transporters SLC1A5 and SLC7A5 as well as the ancillary subunit SLC3A2, which are required for efficient uptake of glutamine and leucine respectively, could strengthen the metabolic capabilities and effector functions of tumor-directed CAR-NK and T cells. Leucine 159-166 solute carrier family 7 member 5 Homo sapiens 54-60 33758168-4 2021 Here, we synthesized three potent inhibitors of human LAT1, which inhibit transport of leucine with IC50 values between 100 and 250 nM, and solved the cryo-EM structures of the corresponding LAT1-4F2hc complexes with these inhibitors bound at resolution of up to 2.7 or 2.8 A. Leucine 87-94 solute carrier family 7 member 5 Homo sapiens 54-58 33011235-14 2021 Functional studies revealed transport of the LAT1 substrate [3H]-L-Leucine and the LRP1 substrate angiopep-2. Leucine 67-74 solute carrier family 7 member 5 Homo sapiens 45-49 33401672-5 2021 Inhibiting the interaction between LAT1 and CD98 heavy chain prevents activation of the mammalian target of rapamycin (mTOR) complex 1 by glutamine and leucine. Leucine 152-159 solute carrier family 7 member 5 Homo sapiens 35-39 33401672-5 2021 Inhibiting the interaction between LAT1 and CD98 heavy chain prevents activation of the mammalian target of rapamycin (mTOR) complex 1 by glutamine and leucine. Leucine 152-159 solute carrier family 7 member 5 Homo sapiens 44-48 31992742-1 2020 L-type amino acid transporter 1 (LAT1) plays a role in transporting essential amino acids including leucine, which regulates the mTOR signaling pathway. Leucine 100-107 solute carrier family 7 member 5 Homo sapiens 0-31 33001560-3 2020 Active Na+ -independent leucine transport across the placenta is mainly attributed to the System L transporters LAT1/SLC7A5 and LAT2/SLC7A8. Leucine 24-31 solute carrier family 7 member 5 Homo sapiens 112-116 33001560-3 2020 Active Na+ -independent leucine transport across the placenta is mainly attributed to the System L transporters LAT1/SLC7A5 and LAT2/SLC7A8. Leucine 24-31 solute carrier family 7 member 5 Homo sapiens 117-123 33001560-5 2020 L-leucine uptake (total dose = 167 mumol/L) was sensitive to LAT1-specific inhibition by JPH203 (EC50 = 2.55 micromol/L). Leucine 2-9 solute carrier family 7 member 5 Homo sapiens 61-65 33001560-8 2020 The application of JPH203 and JX009 in Transwell -based leucine transfer revealed LAT1 as the major accumulative transporter at the apical membrane, but other System L transporters such as LAT2 as rate-limiting for leucine efflux across the basal membrane. Leucine 57-64 solute carrier family 7 member 5 Homo sapiens 83-87 31992742-1 2020 L-type amino acid transporter 1 (LAT1) plays a role in transporting essential amino acids including leucine, which regulates the mTOR signaling pathway. Leucine 100-107 solute carrier family 7 member 5 Homo sapiens 33-37 30696773-6 2019 Inhibition of the amino acid transporter CD98/LAT1 abrogated the leucine-driven mTORC1 activation and reduced NK cell effector function. Leucine 65-72 solute carrier family 7 member 5 Homo sapiens 41-45 30092695-0 2019 l-Leucine influx through Slc7a5 regulates inflammatory responses of human B cells via mammalian target of rapamycin complex 1 signaling. Leucine 0-9 solute carrier family 7 member 5 Homo sapiens 25-31 30092695-10 2019 Conclusion: l-leucine influx through Slc7a5 critically regulates mTORC1 activity and the immunological responses of human B cells. Leucine 12-21 solute carrier family 7 member 5 Homo sapiens 37-43 30996345-6 2019 LLGL2 regulates cell surface levels of a leucine transporter, SLC7A5, by forming a trimeric complex with SLC7A5 and a regulator of membrane fusion, YKT6, to promote leucine uptake and cell proliferation. Leucine 165-172 solute carrier family 7 member 5 Homo sapiens 105-111 31160781-4 2019 LAT1 features a canonical Leu T-fold and exhibits an unusual loop structure on transmembrane helix 6, creating an extended cavity that might accommodate bulky amino acids and drugs. Leucine 26-29 solute carrier family 7 member 5 Homo sapiens 0-4 30996345-6 2019 LLGL2 regulates cell surface levels of a leucine transporter, SLC7A5, by forming a trimeric complex with SLC7A5 and a regulator of membrane fusion, YKT6, to promote leucine uptake and cell proliferation. Leucine 41-48 solute carrier family 7 member 5 Homo sapiens 62-68 30996345-6 2019 LLGL2 regulates cell surface levels of a leucine transporter, SLC7A5, by forming a trimeric complex with SLC7A5 and a regulator of membrane fusion, YKT6, to promote leucine uptake and cell proliferation. Leucine 41-48 solute carrier family 7 member 5 Homo sapiens 105-111 30996345-6 2019 LLGL2 regulates cell surface levels of a leucine transporter, SLC7A5, by forming a trimeric complex with SLC7A5 and a regulator of membrane fusion, YKT6, to promote leucine uptake and cell proliferation. Leucine 165-172 solute carrier family 7 member 5 Homo sapiens 62-68 30696773-6 2019 Inhibition of the amino acid transporter CD98/LAT1 abrogated the leucine-driven mTORC1 activation and reduced NK cell effector function. Leucine 65-72 solute carrier family 7 member 5 Homo sapiens 46-50 30449824-1 2018 L-type amino acid transporter 1 (LAT1) functions to transport large neutral amino acids, such as leucine, isoleucine, valine, phenylalanine, tyrosine, tryptophan, methionine, and histidine. Leucine 97-104 solute carrier family 7 member 5 Homo sapiens 0-31 30449824-1 2018 L-type amino acid transporter 1 (LAT1) functions to transport large neutral amino acids, such as leucine, isoleucine, valine, phenylalanine, tyrosine, tryptophan, methionine, and histidine. Leucine 97-104 solute carrier family 7 member 5 Homo sapiens 33-37 29940911-2 2018 In particular, leucine and glutamine have been shown to be important for growth and proliferation of some breast cancers, and therefore targeting the primary cell-surface transporters that mediate their uptake, L-type amino acid transporter 1 (LAT1) and alanine, serine, cysteine-preferring transporter 2 (ASCT2), is a potential therapeutic strategy. Leucine 15-22 solute carrier family 7 member 5 Homo sapiens 211-242 30029480-4 2018 Both approaches successfully diminished glutamine (ASCT2) and leucine (LAT1) initial-rate transport proportional to transporter protein suppression. Leucine 62-69 solute carrier family 7 member 5 Homo sapiens 71-75 30029480-7 2018 However, intracellular accumulation of radiolabeled glutamine and leucine over longer time periods largely recovered to control levels in ASCT2 and LAT1 knockout cells, respectively, which partially explains the lack of an impaired growth phenotype. Leucine 66-73 solute carrier family 7 member 5 Homo sapiens 148-152 29940911-2 2018 In particular, leucine and glutamine have been shown to be important for growth and proliferation of some breast cancers, and therefore targeting the primary cell-surface transporters that mediate their uptake, L-type amino acid transporter 1 (LAT1) and alanine, serine, cysteine-preferring transporter 2 (ASCT2), is a potential therapeutic strategy. Leucine 15-22 solute carrier family 7 member 5 Homo sapiens 244-248 29940911-3 2018 METHODS: The ASCT2 inhibitor, benzylserine (BenSer), is also able to block LAT1 activity, thus inhibiting both leucine and glutamine uptake. Leucine 111-118 solute carrier family 7 member 5 Homo sapiens 75-79 27412117-4 2016 All prodrugs had affinity for LAT1 studied as competitive inhibition of [14C]-L-leucine in human breast cancer (MCF-7) cell line. Leucine 78-87 solute carrier family 7 member 5 Homo sapiens 30-34 28856713-0 2018 Leucine supplementation after mechanical stimulation activates protein synthesis via L-type amino acid transporter 1 in vitro. Leucine 0-7 solute carrier family 7 member 5 Homo sapiens 85-116 28856713-5 2018 Notably, the expression of L-type amino acid transporter 1 (LAT1), a stimulator of the mTOR pathway, was also increased by mechanical stretching, and siRNA-mediated knockdown partially attenuated leucine-induced p70S6K phosphorylation. Leucine 196-203 solute carrier family 7 member 5 Homo sapiens 27-58 28856713-5 2018 Notably, the expression of L-type amino acid transporter 1 (LAT1), a stimulator of the mTOR pathway, was also increased by mechanical stretching, and siRNA-mediated knockdown partially attenuated leucine-induced p70S6K phosphorylation. Leucine 196-203 solute carrier family 7 member 5 Homo sapiens 60-64 28856713-6 2018 These results suggest that mechanical stretching promotes LAT1 expression and, consequently, amino acid uptake, leading to enhanced leucine-induced activation of protein synthesis. Leucine 132-139 solute carrier family 7 member 5 Homo sapiens 58-62 29422900-4 2018 We provide evidence that SLC7A5-mediated leucine influx contributes to pro-inflammatory cytokine production via mTOR complex 1 (mTORC1)-induced glycolytic reprograming in activated human monocytes/macrophages. Leucine 41-48 solute carrier family 7 member 5 Homo sapiens 25-31 29422900-7 2018 Inhibition of SLC7A5-mediated leucine influx was linked to downregulation of glycolytic metabolism as evidenced by the decreased extracellular acidification rate, suggesting a regulatory role for this molecule in glycolytic reprograming. Leucine 30-37 solute carrier family 7 member 5 Homo sapiens 14-20 29278358-2 2017 Leucine rapidly enters the cell via the L-Type Amino Acid Transporter 1 (LAT1); however, little is known regarding the localisation and distribution of this transporter in human skeletal muscle. Leucine 0-7 solute carrier family 7 member 5 Homo sapiens 40-71 29278358-2 2017 Leucine rapidly enters the cell via the L-Type Amino Acid Transporter 1 (LAT1); however, little is known regarding the localisation and distribution of this transporter in human skeletal muscle. Leucine 0-7 solute carrier family 7 member 5 Homo sapiens 73-77 28516268-2 2017 In a panel of human cancer cell lines, which express the system L transporters LAT1 and LAT2, GPNA inhibits the sodium-independent influx of leucine and glutamine. Leucine 141-148 solute carrier family 7 member 5 Homo sapiens 79-83 28242177-2 2017 In cancer cells, LAT1 is responsible for the cellular uptake of many essential amino acids including leucine that activates mechanistic/mammalian target of rapamycin (mTOR), regulating cancer cell growth. Leucine 101-108 solute carrier family 7 member 5 Homo sapiens 17-21 27567475-6 2016 LAT1-specific inhibitor significantly suppressed leucine uptake and growth of Ty82 human thymic carcinoma cell lines, suggesting that thymic carcinoma takes advantage of LAT1 as a quality transporter and that LAT1-specific inhibitor might be clinically beneficial in therapy for thymic carcinoma. Leucine 49-56 solute carrier family 7 member 5 Homo sapiens 0-4 27567475-6 2016 LAT1-specific inhibitor significantly suppressed leucine uptake and growth of Ty82 human thymic carcinoma cell lines, suggesting that thymic carcinoma takes advantage of LAT1 as a quality transporter and that LAT1-specific inhibitor might be clinically beneficial in therapy for thymic carcinoma. Leucine 49-56 solute carrier family 7 member 5 Homo sapiens 170-174 27567475-6 2016 LAT1-specific inhibitor significantly suppressed leucine uptake and growth of Ty82 human thymic carcinoma cell lines, suggesting that thymic carcinoma takes advantage of LAT1 as a quality transporter and that LAT1-specific inhibitor might be clinically beneficial in therapy for thymic carcinoma. Leucine 49-56 solute carrier family 7 member 5 Homo sapiens 170-174 29695141-1 2018 The large neutral amino acid transporter 1 (LAT1, or SLC7A5) is a sodium- and pH-independent transporter, which supplies essential amino acids (e.g., leucine, phenylalanine) to cells. Leucine 150-157 solute carrier family 7 member 5 Homo sapiens 44-48 29695141-1 2018 The large neutral amino acid transporter 1 (LAT1, or SLC7A5) is a sodium- and pH-independent transporter, which supplies essential amino acids (e.g., leucine, phenylalanine) to cells. Leucine 150-157 solute carrier family 7 member 5 Homo sapiens 53-59 29150487-2 2018 It is activated by growth factors and amino acids, including essential amino acids (EAAs), such as leucine; Leu enters cells via the Leu transporter LAT1-4F2hc (also known as SLC7A5-SLC3A2) and potentially via endocytosis. Leucine 99-106 solute carrier family 7 member 5 Homo sapiens 149-153 29150487-2 2018 It is activated by growth factors and amino acids, including essential amino acids (EAAs), such as leucine; Leu enters cells via the Leu transporter LAT1-4F2hc (also known as SLC7A5-SLC3A2) and potentially via endocytosis. Leucine 99-106 solute carrier family 7 member 5 Homo sapiens 175-181 29150487-2 2018 It is activated by growth factors and amino acids, including essential amino acids (EAAs), such as leucine; Leu enters cells via the Leu transporter LAT1-4F2hc (also known as SLC7A5-SLC3A2) and potentially via endocytosis. Leucine 108-111 solute carrier family 7 member 5 Homo sapiens 149-153 29150487-2 2018 It is activated by growth factors and amino acids, including essential amino acids (EAAs), such as leucine; Leu enters cells via the Leu transporter LAT1-4F2hc (also known as SLC7A5-SLC3A2) and potentially via endocytosis. Leucine 108-111 solute carrier family 7 member 5 Homo sapiens 175-181 29150487-4 2018 Our results show that LAT1 is the major route of Leu entry into cells and mTORC1 activation (~70%), whereas dynamin-dependent endocytosis and macropinocytosis contribute minimally to both (5-15%). Leucine 49-52 solute carrier family 7 member 5 Homo sapiens 22-26 27486861-1 2016 l-type amino acid transporters (LAT1-4) are expressed in various cancer types and are involved in the uptake of essential amino acids such as leucine. Leucine 142-149 solute carrier family 7 member 5 Homo sapiens 32-38 27486861-8 2016 These data show that LAT1 plays an important role in regulating the uptake of essential amino acids such as leucine into endometrial cancer cells. Leucine 108-115 solute carrier family 7 member 5 Homo sapiens 21-25 26724922-3 2016 The activation of mTORC1 by leucine and its derivatives was the consequence of two successive events: the cellular uptake by L-type amino acid transporter 1 (LAT1) responsible for leucine uptake in HeLa S3 cells and the activation of mTORC1 following the transport. Leucine 28-35 solute carrier family 7 member 5 Homo sapiens 125-156 26682754-2 2016 LAT1 (L-type amino acid transporter 1) transports essential amino acids, including leucine, which trigger the downstream mTOR (mammalian target of rapamycin) pathway. Leucine 83-90 solute carrier family 7 member 5 Homo sapiens 0-4 26682754-2 2016 LAT1 (L-type amino acid transporter 1) transports essential amino acids, including leucine, which trigger the downstream mTOR (mammalian target of rapamycin) pathway. Leucine 83-90 solute carrier family 7 member 5 Homo sapiens 6-37 26944194-8 2016 Upregulation of LAT1 by TCDD coincided with increases in leucine uptake by MCF-7 cells in response to TCDD. Leucine 57-64 solute carrier family 7 member 5 Homo sapiens 16-20 26724922-3 2016 The activation of mTORC1 by leucine and its derivatives was the consequence of two successive events: the cellular uptake by L-type amino acid transporter 1 (LAT1) responsible for leucine uptake in HeLa S3 cells and the activation of mTORC1 following the transport. Leucine 28-35 solute carrier family 7 member 5 Homo sapiens 158-162 26724922-3 2016 The activation of mTORC1 by leucine and its derivatives was the consequence of two successive events: the cellular uptake by L-type amino acid transporter 1 (LAT1) responsible for leucine uptake in HeLa S3 cells and the activation of mTORC1 following the transport. Leucine 180-187 solute carrier family 7 member 5 Homo sapiens 125-156 26724922-3 2016 The activation of mTORC1 by leucine and its derivatives was the consequence of two successive events: the cellular uptake by L-type amino acid transporter 1 (LAT1) responsible for leucine uptake in HeLa S3 cells and the activation of mTORC1 following the transport. Leucine 180-187 solute carrier family 7 member 5 Homo sapiens 158-162 26621329-5 2016 DEPe concomitantly induced LAT1/CD98hc protein expression and LAT1-mediated leucine accumulation in BEAS-2B cells. Leucine 76-83 solute carrier family 7 member 5 Homo sapiens 62-66 26101697-2 2015 The four LATs, LAT1 (SLC7A5), LAT2 (SLC7A8), LAT3 (SLC43A1) and LAT4 (SLC43A2), are responsible for the majority of cellular leucine uptake. Leucine 125-132 solute carrier family 7 member 5 Homo sapiens 15-19 26668776-1 2015 L-type amino acid transporter 1 (LAT1) is an L-type amino acid transporter and transports large neutral amino acids such as leucine, isoleucine, valine, phenylalanine, tyrosine, tryptophan, methionine, and histidine. Leucine 124-131 solute carrier family 7 member 5 Homo sapiens 0-31 26668776-1 2015 L-type amino acid transporter 1 (LAT1) is an L-type amino acid transporter and transports large neutral amino acids such as leucine, isoleucine, valine, phenylalanine, tyrosine, tryptophan, methionine, and histidine. Leucine 124-131 solute carrier family 7 member 5 Homo sapiens 33-37 25998567-5 2015 We show that LAPTM4b recruits LAT1-4F2hc to lysosomes, leading to uptake of Leu into lysosomes, and is required for mTORC1 activation via V-ATPase following EAA or Leu stimulation. Leucine 76-79 solute carrier family 7 member 5 Homo sapiens 30-34 25998567-5 2015 We show that LAPTM4b recruits LAT1-4F2hc to lysosomes, leading to uptake of Leu into lysosomes, and is required for mTORC1 activation via V-ATPase following EAA or Leu stimulation. Leucine 164-167 solute carrier family 7 member 5 Homo sapiens 30-34 25613922-12 2015 Expression of SLC7A5 was higher in the basal state in patients with cirrhosis than controls (P < 0.05) but increased with BCAA/LEU only in controls (P < 0.001). Leucine 130-133 solute carrier family 7 member 5 Homo sapiens 14-20 26101697-2 2015 The four LATs, LAT1 (SLC7A5), LAT2 (SLC7A8), LAT3 (SLC43A1) and LAT4 (SLC43A2), are responsible for the majority of cellular leucine uptake. Leucine 125-132 solute carrier family 7 member 5 Homo sapiens 21-27 23525088-5 2013 The metabolic catastrophe caused by loss of Slc7a5 reflected the requirement for sustained uptake of the LNAA leucine for activation of the serine-threonine kinase complex mTORC1 and for expression of the transcription factor c-Myc. Leucine 110-117 solute carrier family 7 member 5 Homo sapiens 44-50 23896327-5 2013 [(3)H]l-leucine uptake and cellular growth activities in CHM were inhibited in a dose-dependent manner by both LAT1 inhibitors. Leucine 7-15 solute carrier family 7 member 5 Homo sapiens 111-115 23954667-8 2013 [(3)H]l-Leucine uptake and cellular growth activities in CMeC-1 were inhibited in a dose-dependent manner by selective LAT1 inhibitors (2-amino-2-norbornane-carboxylic acid, BCH and melphalan, LPM). Leucine 6-15 solute carrier family 7 member 5 Homo sapiens 119-123 22898570-7 2013 The leucine/glutamine antiporter SLC7A5/SLC3A2 and the amino acid sensor MAP4K3 were identified as crucial determinants of signaling leucine availability to downstream targets. Leucine 4-11 solute carrier family 7 member 5 Homo sapiens 33-39 20852181-9 2010 Leucine, but not glutamate, transport significantly increased in the cisplatin-treated group due to the increase in LAT1 (leucine transporter) protein expression. Leucine 0-7 solute carrier family 7 member 5 Homo sapiens 116-120 22736142-8 2012 The uptake of leucine, a representative neutral amino acid, was strictly dependent on LAT1 in MIA Paca-2 cells, and siRNA-mediated knockdown of LAT1 inhibited cell proliferation. Leucine 14-21 solute carrier family 7 member 5 Homo sapiens 98-102 22736142-8 2012 The uptake of leucine, a representative neutral amino acid, was strictly dependent on LAT1 in MIA Paca-2 cells, and siRNA-mediated knockdown of LAT1 inhibited cell proliferation. Leucine 14-21 solute carrier family 7 member 5 Homo sapiens 168-172 22985970-4 2013 METHODS: L6 skeletal muscle cells that had been treated with l-leucine (0.105 g/L) were incubated for 30 min to stimulate the transcription of L-type amino acid transporter-1, CD98, and sodium-coupled neutral amino acid transporter-2 and increase activating transcription factor-4 protein, which is dependent on the mTORC1 signaling pathway. Leucine 61-70 solute carrier family 7 member 5 Homo sapiens 143-174 22985970-4 2013 METHODS: L6 skeletal muscle cells that had been treated with l-leucine (0.105 g/L) were incubated for 30 min to stimulate the transcription of L-type amino acid transporter-1, CD98, and sodium-coupled neutral amino acid transporter-2 and increase activating transcription factor-4 protein, which is dependent on the mTORC1 signaling pathway. Leucine 61-70 solute carrier family 7 member 5 Homo sapiens 176-180 22007000-2 2011 Here, we report that prostate cancer cells coordinate the expression of LAT1 and LAT3 to maintain sufficient levels of leucine needed for mTORC1 signaling and cell growth. Leucine 119-126 solute carrier family 7 member 5 Homo sapiens 72-76 19890975-6 2010 [3H]L-leucine efflux from ARPE-19 cells was trans-stimulated by substrates of LAT1 and LAT2 through the obligatory exchange mechanism of system L. Although RT-PCR analysis demonstrated that LAT1 and LAT2 mRNA are expressed in ARPE-19 cells, the LAT1 mRNA concentration is 42-fold higher than that of LAT2. Leucine 6-13 solute carrier family 7 member 5 Homo sapiens 78-82 19890975-0 2010 Involvement of LAT1 and LAT2 in the high- and low-affinity transport of L-leucine in human retinal pigment epithelial cells (ARPE-19 cells). Leucine 72-81 solute carrier family 7 member 5 Homo sapiens 15-19 19890975-6 2010 [3H]L-leucine efflux from ARPE-19 cells was trans-stimulated by substrates of LAT1 and LAT2 through the obligatory exchange mechanism of system L. Although RT-PCR analysis demonstrated that LAT1 and LAT2 mRNA are expressed in ARPE-19 cells, the LAT1 mRNA concentration is 42-fold higher than that of LAT2. Leucine 6-13 solute carrier family 7 member 5 Homo sapiens 190-194 19890975-6 2010 [3H]L-leucine efflux from ARPE-19 cells was trans-stimulated by substrates of LAT1 and LAT2 through the obligatory exchange mechanism of system L. Although RT-PCR analysis demonstrated that LAT1 and LAT2 mRNA are expressed in ARPE-19 cells, the LAT1 mRNA concentration is 42-fold higher than that of LAT2. Leucine 6-13 solute carrier family 7 member 5 Homo sapiens 190-194 20375792-8 2010 Thus, our findings indicated that most l-leucine uptake in OVCAR-3 cells was mediated by LAT1. Leucine 39-48 solute carrier family 7 member 5 Homo sapiens 89-93 15980244-8 2005 [3H]L-Leucine efflux from TR-iBRB2 cells was trans-stimulated by substrates of LAT1. Leucine 6-13 solute carrier family 7 member 5 Homo sapiens 79-83 20061171-10 2010 At baseline, most LAT1 substrates varied inversely with plasma leucine, and their calculated rates of brain uptake were 20-68% below normal. Leucine 63-70 solute carrier family 7 member 5 Homo sapiens 18-22 16827134-9 2006 The majority of [14C]L-leucine uptake is, therefore, mediated by LAT2 and LAT1 in FOB and Saos2 cells, respectively. Leucine 21-30 solute carrier family 7 member 5 Homo sapiens 74-78 20641401-4 2004 One of the transporters, described as the major vehicle of large, neutral aa such as phenylalanine, leucine, and tyrosine, is known as the L system (L-type aa transporter 1; LAT1) and is independent of sodium for the transport of these aa (5). Leucine 100-107 solute carrier family 7 member 5 Homo sapiens 174-178 17956316-4 2007 Other molecules such as the heterodimeric amino acid transporter, CD98, which provides the principal route for cellular uptake of leucine, an amino acid implicated in regulating TOR, also appear to have important effects. Leucine 130-137 solute carrier family 7 member 5 Homo sapiens 66-70 14977877-7 2004 Serum, thrombin, and angiotensin II likewise stimulated L-leucine transport by inducing LAT1 expression. Leucine 56-65 solute carrier family 7 member 5 Homo sapiens 88-92 15863273-5 2005 The majority of [14C] L-leucine uptake was, therefore, mainly mediated by LAT2 in the HNOK and by LAT1 in the KB cells. Leucine 22-31 solute carrier family 7 member 5 Homo sapiens 98-102 11557028-8 2001 When loaded intracellularly, L-leucine and L-glutamine but not L-alanine are effluxed by extracellular substrates, confirming that hLAT1 mediates an amino acid exchange. Leucine 29-38 solute carrier family 7 member 5 Homo sapiens 131-136 15036654-4 2004 The majority of [14C]l-leucine uptake is, therefore, mediated by LAT1. Leucine 21-30 solute carrier family 7 member 5 Homo sapiens 65-69 12493540-9 2003 The level of efflux mediated by hLAT1 was highly stimulated by extracellularly applied L-Leu, suggesting exchange of [(125)I]IMT and L-Leu via hLAT1. Leucine 87-92 solute carrier family 7 member 5 Homo sapiens 32-37 12493540-9 2003 The level of efflux mediated by hLAT1 was highly stimulated by extracellularly applied L-Leu, suggesting exchange of [(125)I]IMT and L-Leu via hLAT1. Leucine 87-92 solute carrier family 7 member 5 Homo sapiens 143-148 12493540-9 2003 The level of efflux mediated by hLAT1 was highly stimulated by extracellularly applied L-Leu, suggesting exchange of [(125)I]IMT and L-Leu via hLAT1. Leucine 133-138 solute carrier family 7 member 5 Homo sapiens 32-37 12493540-9 2003 The level of efflux mediated by hLAT1 was highly stimulated by extracellularly applied L-Leu, suggesting exchange of [(125)I]IMT and L-Leu via hLAT1. Leucine 133-138 solute carrier family 7 member 5 Homo sapiens 143-148 12117417-7 2002 In addition, [(3)H]methionine efflux was trans -stimulated by leucine and phenylalanine even in the presence of an inwardly directed methionine gradient, demonstrating concentrative transport by both LAT1 and LAT2. Leucine 62-69 solute carrier family 7 member 5 Homo sapiens 200-204 12225859-8 2002 The majority of [14C]L-leucine uptake is, therefore, mediated by LAT1 in T24 cells. Leucine 21-30 solute carrier family 7 member 5 Homo sapiens 65-69 11564694-6 2001 Coinjection of cRNAs for human 4F2 heavy chain and human LAT1 light chain stimulated the uptake of phenylalanine > tyrosine > leucine > tryptophan (100 microM) and of 3,3"-diiodothyronine > rT(3) approximately T(3) > T(4) (10 nM), which in all cases was Na(+) independent. Leucine 132-139 solute carrier family 7 member 5 Homo sapiens 57-61 34836160-3 2021 In a group design, healthy males consumed a mixed carbohydrate (0.75 g kg-1) crystalline amino acid (0.25 g kg-1) beverage enriched to 25% and 30% with LAT1 substrates L-(1-13C)leucine (LEU) and L-(ring-2H5)phenylalanine (PHE), respectively, at rest (FED: n = 7, 23 +- 5 y, 77 +- 4 kg) or after a bout of resistance exercise (EXFED: n = 7, 22 +- 2 y, 78 +- 11 kg). Leucine 177-184 solute carrier family 7 member 5 Homo sapiens 152-156 34427144-6 2022 Of 7 Leu AAT genes expressed by D3 only the activity of SLC7A5-SLC3A2/LAT1-4F2HC (LAT1), SLC43A2/LAT4 (LAT4) and sodium-dependent AATs, SLC6A15/B0AT2 (B0AT2), and SLC7A7/y+LAT1 (y+LAT1) were calculated to be required for Leu uptake. Leucine 5-8 solute carrier family 7 member 5 Homo sapiens 56-62 34427144-6 2022 Of 7 Leu AAT genes expressed by D3 only the activity of SLC7A5-SLC3A2/LAT1-4F2HC (LAT1), SLC43A2/LAT4 (LAT4) and sodium-dependent AATs, SLC6A15/B0AT2 (B0AT2), and SLC7A7/y+LAT1 (y+LAT1) were calculated to be required for Leu uptake. Leucine 221-224 solute carrier family 7 member 5 Homo sapiens 56-62 34427144-6 2022 Of 7 Leu AAT genes expressed by D3 only the activity of SLC7A5-SLC3A2/LAT1-4F2HC (LAT1), SLC43A2/LAT4 (LAT4) and sodium-dependent AATs, SLC6A15/B0AT2 (B0AT2), and SLC7A7/y+LAT1 (y+LAT1) were calculated to be required for Leu uptake. Leucine 221-224 solute carrier family 7 member 5 Homo sapiens 82-86 34427144-7 2022 Therefore, D3 Leu transport may be mediated by a potentially physiologically relevant functional cooperation between the known BBB AAT, LAT1 and obligatory exchange (y+LAT1), facilitative diffusion (LAT4), and sodium symporter (B0AT2) transporters. Leucine 14-17 solute carrier family 7 member 5 Homo sapiens 136-140 34194623-2 2021 LAT1 transports large neutral amino acids, including leucine, which activates mTOR, and is highly expressed in human cancers. Leucine 53-60 solute carrier family 7 member 5 Homo sapiens 0-4 34349180-4 2021 Here we show that acetylation of leucine switches its uptake into cells from the L-type amino acid transporter (LAT1) used by leucine to organic anion transporters (OAT1 and OAT3) and the monocarboxylate transporter type 1 (MCT1). Leucine 33-40 solute carrier family 7 member 5 Homo sapiens 112-116 34503187-4 2021 LAT1 expression could mediate leucine uptake, mTORC1 signaling, and cell proliferation. Leucine 30-37 solute carrier family 7 member 5 Homo sapiens 0-4 34503187-11 2021 LAT1 expression then mediated leucine uptake, enhanced mTORC1 signaling, and eventually resulted in AI resistance. Leucine 30-37 solute carrier family 7 member 5 Homo sapiens 0-4 34349180-4 2021 Here we show that acetylation of leucine switches its uptake into cells from the L-type amino acid transporter (LAT1) used by leucine to organic anion transporters (OAT1 and OAT3) and the monocarboxylate transporter type 1 (MCT1). Leucine 126-133 solute carrier family 7 member 5 Homo sapiens 112-116 34349180-5 2021 Both the kinetics of MCT1 (lower affinity compared to LAT1) and the ubiquitous tissue expression of MCT1 make it well suited for uptake and distribution of N-acetyl-L-leucine. Leucine 167-174 solute carrier family 7 member 5 Homo sapiens 54-58 34349180-6 2021 MCT1-mediated uptake of a N-acetyl-L-leucine as a prodrug of leucine bypasses LAT1, the rate-limiting step in activation of leucine-mediated signalling and metabolic process inside cells such as mTOR. Leucine 37-44 solute carrier family 7 member 5 Homo sapiens 78-82 34349180-6 2021 MCT1-mediated uptake of a N-acetyl-L-leucine as a prodrug of leucine bypasses LAT1, the rate-limiting step in activation of leucine-mediated signalling and metabolic process inside cells such as mTOR. Leucine 61-68 solute carrier family 7 member 5 Homo sapiens 78-82 34349180-6 2021 MCT1-mediated uptake of a N-acetyl-L-leucine as a prodrug of leucine bypasses LAT1, the rate-limiting step in activation of leucine-mediated signalling and metabolic process inside cells such as mTOR. Leucine 124-131 solute carrier family 7 member 5 Homo sapiens 78-82 34152720-7 2021 Further study demonstrated that supplement with leucine could restrain SASP secretion, and baicalein could significantly increase leucine level through down-regulation of BCAT1 and up-regulation of SLC7A5 expression. Leucine 48-55 solute carrier family 7 member 5 Homo sapiens 198-204 34152720-7 2021 Further study demonstrated that supplement with leucine could restrain SASP secretion, and baicalein could significantly increase leucine level through down-regulation of BCAT1 and up-regulation of SLC7A5 expression. Leucine 130-137 solute carrier family 7 member 5 Homo sapiens 198-204 34201429-5 2021 Leucine uptake by BC cells is through L-Type Amino Acid Transporter 1 (LAT1). Leucine 0-7 solute carrier family 7 member 5 Homo sapiens 38-69 34201429-5 2021 Leucine uptake by BC cells is through L-Type Amino Acid Transporter 1 (LAT1). Leucine 0-7 solute carrier family 7 member 5 Homo sapiens 71-75 34201429-10 2021 LAT1 activity was determined by uptake of 3H-leucine. Leucine 45-52 solute carrier family 7 member 5 Homo sapiens 0-4 34201429-14 2021 The results showed obese-ADS-induced LAT1 activity by increasing transporter affinity for leucine. Leucine 90-97 solute carrier family 7 member 5 Homo sapiens 37-41 34145066-5 2021 T cells from older adults have an increased expression of the plasma membrane leucine transporter SLC7A5 to provide a cytosolic amino acid source. Leucine 78-85 solute carrier family 7 member 5 Homo sapiens 98-104 35501367-5 2022 SCRIB interacts with SLC3A2, a heteromeric component of leucine amino acid transporter SLC7A5. Leucine 56-63 solute carrier family 7 member 5 Homo sapiens 87-93 35379539-3 2022 The traditional model of PKU neuropathophysiology dictates blood Phe over-representation directs asymmetric blood:brain barrier amino acid transport through the LAT1 transporter with subsequent increased cerebral Phe concentration and low concentrations of tyrosine (Tyr), tryptophan (Trp), leucine (Leu), valine (Val), and isoleucine (Ile). Leucine 291-298 solute carrier family 7 member 5 Homo sapiens 161-165 35379539-3 2022 The traditional model of PKU neuropathophysiology dictates blood Phe over-representation directs asymmetric blood:brain barrier amino acid transport through the LAT1 transporter with subsequent increased cerebral Phe concentration and low concentrations of tyrosine (Tyr), tryptophan (Trp), leucine (Leu), valine (Val), and isoleucine (Ile). Leucine 300-303 solute carrier family 7 member 5 Homo sapiens 161-165 35408997-3 2022 To support future CNS drug-delivery development based on LAT-1 targeting, we established an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) assay for stable isotopically labeled leucine ((13C6, 15N)-L-leucine), with a dynamic range of 0.1-1000 ng/mL that can be applied for the functional testing of LAT-1 activity when combined with specific inhibitors and, consequently, the LAT-1 inhibition capacity of new compounds. Leucine 208-215 solute carrier family 7 member 5 Homo sapiens 57-62 35408997-3 2022 To support future CNS drug-delivery development based on LAT-1 targeting, we established an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) assay for stable isotopically labeled leucine ((13C6, 15N)-L-leucine), with a dynamic range of 0.1-1000 ng/mL that can be applied for the functional testing of LAT-1 activity when combined with specific inhibitors and, consequently, the LAT-1 inhibition capacity of new compounds. Leucine 208-215 solute carrier family 7 member 5 Homo sapiens 330-335 35408997-3 2022 To support future CNS drug-delivery development based on LAT-1 targeting, we established an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) assay for stable isotopically labeled leucine ((13C6, 15N)-L-leucine), with a dynamic range of 0.1-1000 ng/mL that can be applied for the functional testing of LAT-1 activity when combined with specific inhibitors and, consequently, the LAT-1 inhibition capacity of new compounds. Leucine 208-215 solute carrier family 7 member 5 Homo sapiens 407-412 35408997-7 2022 In addition, the (13C6, 15N)-L-leucine uptake was determined on two human brain capillary endothelial cell lines (NKIM-6 and hCMEC/D3), which were characterized for their expressional differences of LAT-1 at the protein and mRNA level and the surface amount of CD98. Leucine 31-38 solute carrier family 7 member 5 Homo sapiens 199-204 35408997-7 2022 In addition, the (13C6, 15N)-L-leucine uptake was determined on two human brain capillary endothelial cell lines (NKIM-6 and hCMEC/D3), which were characterized for their expressional differences of LAT-1 at the protein and mRNA level and the surface amount of CD98. Leucine 31-38 solute carrier family 7 member 5 Homo sapiens 261-265 35408997-9 2022 Furthermore, the (13C6, 15N)-L-leucine uptake was significantly higher in hCMEC/D3 cells compared to NKIM-6 cells, which correlated with higher expression of LAT-1 and a higher surface amount of CD98. Leucine 31-38 solute carrier family 7 member 5 Homo sapiens 158-163 35408997-9 2022 Furthermore, the (13C6, 15N)-L-leucine uptake was significantly higher in hCMEC/D3 cells compared to NKIM-6 cells, which correlated with higher expression of LAT-1 and a higher surface amount of CD98. Leucine 31-38 solute carrier family 7 member 5 Homo sapiens 195-199 35408997-10 2022 Therefore, the UPLC-MS/MS quantification of ((13C6, 15N)-L-leucine is a feasible strategy for the functional characterization of LAT-1 activity in cells or tissue. Leucine 59-66 solute carrier family 7 member 5 Homo sapiens 129-134 35431492-2 2022 LAT1 supports cell growth by importing leucine and thereby stimulates mammalian target of rapamycin (mTOR) activity, a phenomenon often observed in cancer cells. Leucine 39-46 solute carrier family 7 member 5 Homo sapiens 0-4